Navigation Links
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Date:7/2/2008

ting stent with clinically important benefits for patients," said Gregg W. Stone, M.D., Columbia University Medical Center; chairman, Cardiovascular Research Foundation, New York; and principal investigator of the SPIRIT III U.S. pivotal clinical trial for XIENCE V.

Clinical Data Supporting XIENCE V

The robust clinical program for XIENCE V includes long-term data from a total of 1,362 patients enrolled in the SPIRIT FIRST, SPIRIT II and SPIRIT III trials, as well as continued access and post-approval programs that will enroll more than 14,000 XIENCE V patients.

The FDA approved XIENCE V based, in large part, on superior results from the 1,002 patient SPIRIT III U.S. pivotal clinical trial, in which XIENCE V demonstrated statistical superiority to TAXUS on the study's primary endpoint of in-segment late loss (vessel renarrowing) at eight months, with a statistically significant 50 percent reduction (mean, 0.14 mm for XIENCE V vs. 0.28 mm for TAXUS). XIENCE V also demonstrated statistical non-inferiority to TAXUS in the co-primary endpoint of target vessel failure (TVF, cardiac events related to the stented vessel) at nine months, with an observed 20 percent reduction (7.2 percent for XIENCE V vs. 9.0 percent for TAXUS). TVF is a composite clinical measure of safety and efficacy outcomes defined as cardiac death, heart attack (myocardial infarction or MI) or target vessel revascularization (TVR).

In May 2008, Abbott presented two-year data from the SPIRIT III trial demonstrating that XIENCE V continues to deliver positive clinical benefits for patients. At two years, the XIENCE V demonstrated the following key results:

-- A 45 percent reduction in the risk of major adverse cardiac events (MACE) compared to TAXUS (7.3 percent for XIENCE V vs. 12.8 percent for TAXUS, p-value=0.004)*. MACE is an important composite clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (MI) or ischemia-driv
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
2. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
3. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
4. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
5. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
8. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
9. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
10. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
11. Medicare Approves in Home Sleep Apnea Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015 According to a new ... Storage Systems, Thawing Equipment, Alarms), by Biospecimen (Human Tissue, ... End User - Global Forecast to 2020", published by ... USD 3,731.03 Million by 2020 from USD 2,150.48 Million ... 2015 and 2020. Browse 74 Tables ...
(Date:8/28/2015)... CA (PRWEB) , ... August 28, 2015 , ... ... in Personalized Medicine, presented two studies at the International Spine Intervention Society’ ... July 28th, 2015 through to August 1st, 2015. With a focus on evidence-based ...
(Date:8/28/2015)... ... August 28, 2015 , ... Pittcon ... and will present a session on chemical spectroscopic imaging at JASIS 2015 (Japan ... is Asia’s largest analytical and scientific instruments show which will be held at ...
(Date:8/28/2015)... 28, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell ... ended June 30, 2015, corporate highlights, and near-term ... are available at www.sedar.com ,  www.edgar.com ... "RepliCel expects to launch its RCS-01 treatment ...
Breaking Biology Technology:Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5
... ... Line Screening. The two companies aim to further educate the population about vascular ... peripheral arterial disease screening . Life Line Screening will distribute the foundation’s educational ... to the foundation. , ...
... , Opinion ... the Next Decade , WASHINGTON, Dec. 9 On Tuesday, December ... U.S., hosted The Decade-2 Education Forum ... math and science to America,s students and was sponsored by Amgen , ...
... , , VANCOUVER, Dec. 8 /PRNewswire/ - Sirius ... Wagner has been appointed President and Chief Executive Officer, replacing ... his strong leadership as President and CEO over the last ... the commercialization phase in a very short period of time. ...
Cached Biology Technology:Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum 2Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum 3Sirius Genomics Announces Change in Leadership 2
(Date:8/28/2015)... 2015 According to a new ... Assessment Type (Pen & Paper Based, Hosted, Biometrics), Service, ... Academic Research), Vertical and Region - Global Forecast to ... to grow from USD 2.4 Billion in 2015 to ... Growth Rate (CAGR) of 25.6% from 2015 to 2020. ...
(Date:8/26/2015)... , August 26, 2015 The ... and Five Factor), Application (Travel & Immigration, Government, Banking, ... Global Forecast to 2020", published by MarketsandMarkets, Multi-Factor Authentication ... 2020, growing at a CAGR of 17.7% between 2015 ... 82 F igures spread through 169 ...
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 ... systems, announced today it will unveil its "Guardian S" ... at the National Tactical Officers Association Conference on August ... Guardian S is the first-ever commercially available energetically autonomous ... research and in-field trials and is protected by more ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3
... The next International Workshop and Conference on Network ... 2008. Its aim is to bring together leading ... analysts, modelling experts, visualisation specialists, and others) to ... will focus on practitioners, and teachers in network ...
... a person develops a sore or a boil, it erupts, ... Then it resolves and flattens into the skin, often leaving ... plays out in the blood vessels. However, when there is ... blood vessels to recover from inflammation atherosclerosis or hardening ...
... a license agreement between the CSIRO/Australian Capital Ventures Limited ... way for large scale commercial crops of BARLEYmax ... breeding techniques," says the Director of the CSIRO Food ... twice the amount of insoluble and soluble fibre found ...
Cached Biology News:Failure to bridle inflammation spurs atherosclerosis 2
Miniature FRENCH Pressure Cell with 3.7ml capacity; pressure up to 20,000 psi....
... for IVF are designed for human in ... of setup and operation, and convenience. ... continuously displayed on the control panel. Our ... printed by way of the thermal printer ...
6 x Blend of rTth DNA Polymerase and Tli to provide optimized amounts of both 5-3 and 3-5 proofreading activity...
... Transcriptase is a recombinant Moloney murine ... Reverse Transcriptase is similar to MuLV ... recommended usage. MuLV reverse transcriptase is ... uses single-stranded RNA as a template ...
Biology Products: